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Abstract
Recent advances in nanotechnology, biotechnology, bioinformatics, and materials science have prompted novel
developments in the field of nanomedicine. Enhancements in the theranostics, computational information, and
management of diseases/disorders are desperately required. It may now be conceivable to accomplish checked
improvements in both of these areas utilising nanomedicine. This scientific and concise review concentrates on the
fundamentals and potential of nanomedicine, particularly nanoparticles and their advantages, nanoparticles for siRNA
conveyance, nanopores, nanodots, nanotheragnostics, nanodrugs and targeting mechanisms, and aptamer nanomedicine.
The combination of various scientific fields is quickening these improvements, and these interdisciplinary endeavours
to have significant progressively outstretching influences on different fields of research. The capacities of nanomedicine
are immense, and nanotechnology could give medicine a completely new standpoint.
Keywords: nanomedicine, nanotechnology, nanoparticles

dicine, nanostructured drugs with effective site-targeting,
nanopharmaceuticals, nano-imaging, nanoplat forms, nanotheranostics and nano-drug delivery, nano-immunochemotherapy, and post-nano approaches [such as multistage
vector (MSV) platform] will run and enhance the future
development of nanomedicine, personalised medicine,
and targeted therapy.7–10

Introduction
The first utilisation of the trademark frameworks in ‘nanotechnology' (but preceding use of that name) was in
"There's Plenty of Room at the Bottom," a speech given by
physicist Richard Feynman at an American Physical
Society meeting at Caltech on December 29, 1959.1
Nanotechnology refers broadly to a field of applied
science and technology whose unifying theme is the
control of matter on the molecular level in scales smaller
than 1 micrometer, normally 1 to 100 nanometers, and
the fabrication of devices within that size range.2 Nanomedicine is the design and development of theranostics
tools diverged by the nanoscopic scale of its delivery
vehicles and diagnostic agents.3,4 Briefly, Nanomedicine
is an applied, practiced, and utilised nanotechnology in
the field of medicine.5

Nanoparticles. Nanoparticles (NPs) are particles, typically
less than 200 nm in diameter, which usually comprise of
lipids or polymers. NPs are capable of delivering drugs
over epi-endothelial barriers and spatially limit through
active-passive targeting.11 Polyvalent ornament of an
NP's surface with a ligand can assuage binding to a
biomarker that is particularly overrepresented in
targeted cells, and activate receptor-mediated
endocytosis. It has extensive significance for targeted
delivery. The ligands used to adjust NPs include
antibodies, aptamers, engineered antibody fragments,
peptides, proteins, and small molecules.12,13

Nanomedicine has provided some novel explanations and
solutions. There are a lot of pharmaceutical companies
endeavouring to advance targeted drug delivery using
nanotechnology. Some of the existing drugs based on
nanotechnology have the potential to revolutionise our
understanding of human health and disorders. It also
offers an assurance of a transformed portrait of better
health care, health economics, and personalised medicine,
with the eventual aim being an upgraded quality-of-life.6
Advances in the progression of lipid-based nanome

Some of the NPs are elucidated herein. Arginine–glycine–
aspartate-grafted NPs can target avb3 integrin overexpressed by the tumour endothelium, and extravasate
more conveniently. They invade the tumour through the
retention effect and augment permeability.14 A
nanomedicine contrived of pegylated chitosan NPs with
conjugated anti-transferrin receptor antibodies are able
42

August 2017 | Vol. 21 | No. 2

Bionanomedicine: A “Panacea” In Medicine? 43

to carry a blood–brain-barrier-impermeable caspase
inhibitor to the brain.15 The arrangement of solid lipid
NPs are laminated with the mucoadhesive polymer chitosan for intestinal absorption of insulin.16-18 Application
of nanocrystalline solid dispersions, PEG-PLGA NPs,
nanoparticle precipitates, particles, and liposomes can
be applied for the management of pulmonary arterial
hypertension.19-20
Benefits of Nanoparticles. Benefits include the advancement of nanoparticles for screening and theranostics
purposes, DNA sequencing applying nanopores, manufacture of drug delivery systems and single-virus detection,
the significance and current advances in gene/drug delivery
to cancer cells, the molecular imaging and diagnosis of
cancer by targeted functional nanoparticles, the development and potential applications of nanoscale blueprints
in medical management and diagnosis, the use of nanoparticles for stem cell tracking, differentiation, biosensing,
transplantation, magnetic nanoparticle and quantum dotbased applications in tissue engineering and stem cells
in humans, similar to nano-regenerative medicine.21
Nanoparticles for siRNA Delivery. Some requirements
of nanoparticles to permit small interfering RNA (siRNA)
consignment into the tumour include being very minuscule
(size no bigger than 1000 nm), biocompatible, biodegradable, depletion of immuno stimulatory properties, and
can avoid rapid hepatic/renal clearance. Some of them
are lipid complex (cationic liposomes, lipoplexes, etc.),
conjugated polymers (cholesterol, polymer-PEG, etc.),
and cationic polymers (chitosan, atelocollagen, etc.).22
Nanoparticles serve as conveyance vectors for siRNA
and present plentiful benefits over stripped siRNA
conveyance because of its capability to adjust siRNA
while disseminating higher groupings of siRNA, specifically into tumour destinations. Furthermore, some of
these nanoparticles can be changed with high fondness
ligands to correctly target siRNA, specifically in the tumour.
These nanoparticles can serve to advance controlled
discharge, and when planned accurately they can give a
protected and solid stage for siRNA conveyance for the
management of cancer and other disorders.23, 24
Nanopores. The stream of DNA via nanopores can be
utilised to separate low duplicate quantities of DNA,
allowing extremely fast genome sequencing. The primary
exhibit of this guideline utilised a variety of round and
hollow gold nanotubules with inward widths as little as
1.6 nanometres. Positive ions were rejected, and negative
ions were transported through the membrane at the point
when the tubules were charged positively. Interestingly,
only positive ions went through when the film was
adversely
charged.25 Recently,
nanopore-based
electrochemical and nucleic acids sensors can be used to
detect nucleic acids selectively. It is a potentiometric
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sensing
blueprint
from
Nernst–Planck/Poisson
perspective for nucleic acid hybridisation.26
Nanodots. Fluorescent nanoparticles, for example,
'quantum dots',27 PEBBLES (probes encapsulated by
biologically localised embedding) and perfluorocarbon
particles, possibly conquer these issues. ‘Quantum dot'
nanocrystals',28 for the case, are made to a few nanometres in diameter with an almost boundless scope of
pointedly characterised hues. The particles are edgy,
utilising white light and can be connected to biomolecules
to frame seemingly perpetual delicate probes. On a
fundamental level, separate natural occasions can be
checked, all the while labelling distinctive proteins or
DNA sequences with nanodots of a particular colour.
Nanodots are suitable platforms for advancement of
photoluminescence-based sensing schemes.29
Nanotheragnostic. Nanotheragnostic (theragnostic nanoparticles), or theragnostic nanomedicines, are incorporated
nano particulate frameworks that analyse, convey a focus
on treatment, and screen reactions to treatment.30
Nanotheragnostic regimens are useful for management
of cancer, inflammatory liver disease,31 cardiovascular
diseases (i.e. atherosclerosis, thrombosis), and have a
promising application in arthritis (e.g. rheumatoid arthritis),
neurodegenerative diseases, age-related macular degeneration, psoriasis, atherosclerosis, and various bloodstream
bacterial infections.32,33
The four fundamental components that ought to be
satisfied in the structure of nanotheragnostics are the
biodegradable nanocarrier material (based on hybrid
materials, an inorganic component, and an organic matrix),
the signal emitter or imaging agent (exclusive optical,
magnetic, or radioactive hallmark), the medication or
remedial molecule, and changes to the later component
based on passive-active delivery strategies.34, 35
Magnificently, theragnostic nanotools would result in a
multimodality imaging procedure mixed with a multidrug nanocarrier, in addition to supplementary treatment
techniques (i.e. photodynamic treatment, hyperthermia,
and photothermal treatment). Nanotheragnostics and
image-guided drug delivery are relied upon to empower
"precise and personalised" medicine.35,36
Nanodrugs and Targeting Mechanisms. Nanodrugs in
destructive tissues has uptake and aggregation. The two
can happen through two systems, i.e. "uninvolved focusing
on" and "dynamic focusing on". Aloof focusing on
depends on both the size of the medication bearers and
the cracked neovasculature of the tumour. Inactive
aggregation at the tumour site is anticipated to occur
through Enhanced Permeability and Retention (EPR)
effect. With the more drawn out blood course time
accomplished by stealth alteration (e.g. PEGyla tion),
expanded gathering of NPs is conceivable through the
EPR effect. EPR happens because of the expanded
August 2017 | Vol. 21 | No. 2

44 Anurogo, et al.

vessel defectiveness and debilitated lymphatic function
typically observed in tumour tissue; this allows nanomaterials to enter and amass there.21,37,38
Dynamic focusing of nanomaterials is being inves
tigated as a strategy to allow spatial localisation by
purposefully homing NPs to actively diseased regions
while obliterating off-target adverse effects in healthy
tissue. It is achieved by functionalization of their
surface with bioactive molecules, using engineered
antibodies, transferrin, folic acid, and enzymes which
perceive and interplay with cancer-specific targets
overexpressed on the surface of cancerous cells.39
The recent bioactive molecule, QD242-encapsulated
polymeric nanoparticles (NPs) functionalised with a
peptide (Cys-Plec-1 targeted peptides or cys-PTP), carefully
fastened to Plectin-1 (Plec-1). Plec-1 is a Biomarker of
Pancreatic ductal adenocarcinoma (PDAC).40 Active
targeting to accomplish efficacious nanome dicine
congeries in tumour tissue is confutable, as some experts
strive to construct original and creative approaches for
active tumour targeting.21,31 The most commonly used
targeting moieties are mono-clonal antibodies or antigen
binding fragments, antibody fragments, and single chain
variable fragments for active targeting. The latter being
favoured because of its decreased immunogenicity and
high target specificity.21,31
Aptamer Nanomedicine. Aptamer nanomedicine is a
rising, and propitious class of therapeutics used to locate
the difficulties faced by recent cancer treatments. It
might address restrictiveness of different ligands for
targeted treatment in oncology and profoundly perfect
with combined medication treatment. Nevertheless, the
strategy would require a better comprehension of drugloading efficiency, drug-releasing mechanisms, and carrier
design.41,42
Micro-RNA (miRNA), small hairpin RNA (shRNA), small
interfering RNA (siRNA), and antisense oligonucleotides
are engineered for knocking down a specific gene
(deleting a gene function) to murder definite types of
cells. Conversely, plasmid DNA or mRNA are used for
transfection to deliver a certain gene (enumerating a
gene function) to heal a disease. Up to now, most
research focuses on the development of aptamermediated miRNA, shRNA, or siRNA delivery systems
for gene silencing applications. This is an emerging
class of gene therapy that is particularly reassuring for
cancer treatment.41,42
The antinucleolin aptamer, AS1411, coupled to this
liposomal design, for breast cancer cell targeting, executed
cancer cells with high specificity. This aptamer-doxorubicin liposome formulation hindered breast tumour
growth prompted by oestrogen, as no significant or
important growth of the tumour was detected in the
Makara J. Health Res.

group treated with the aptamer-doxorubicin liposome,
while the size of the tumour in the control group raised
166%.21,43,44 Another example is 5-fluorouracil (5-FU)
combined with AS1411 aptamer (NP-5-FU-APTAS1411),
which can be used to effectively manage gastric cancer.45
Related to drug delivery, the most effortless strategy for
aptamer-based nucleic acid delivery is to connect the
therapeutic nucleic acid directly to the aptamer. This is
famous as an aptamer-therapeutic nucleic acid chimaera.
The experts have created functional DNA nano structures
to convey the chemotherapy medication to resistant
cancer cells. These nanostructures comprise of two
components, a DNA aptamer and a double-stranded
DNA (dsDNA). Recently, nucleic acid–based nano
devices have prompted energising molecular biotech
nologies to the top of the line biological imaging.42, 46, 47
The chimaeras Chi-29b and GL21.T-let are supple
mentary examples of direct conjugation of the aptamer
to a therapeutic nucleic acid. Chi-29b consists of an
antimucin 1 (MUC1) aptamer and miRNA miR-29b for
ovarian cancer treatment.21,42,48 It becomes illuminating
that the critical steps for clinical translation of
nanotherapeutics need further inter national and
interdisciplinary efforts, where the entire stakeholder
community is involved from bench to bedside. The
period of nanomedicine is ready to develop and mature
in the following couple of decades; integrating elements
of personalised and precision medicine. It will influence
the therapeutic world in an effective and everlasting
way.
Transcriptomics Tools for Nanomedicine. The design
of nanobiomedicine-based drugs could only be feasible
with the certain incorporation of solid assistant tools.49
Bioinformatics, as the interdisciplinary field of biology
and computer science, is playing a cardinal role in
designing nanobiomedicine-based drugs.50,51 Due to the
rising importance of the transcriptomics approach,
bioinformatics is adjusted to cope with this development
as well.52 The Vienna RNA Package is one of the tools
that could be utilised to design siRNA.53 The theoretical
basis for siRNA design is a solid comprehension of
chemical kinetics and thermodynamics, especially the
modelling of transition states between compounds.54
The Vienna RNA Package also provides tools for
secondary structure prediction, multiple sequence
alignments, and others. However, the rising importance
of transcriptomics is still strongly correlated with the
recent advances in proteomics. The important role of
Transcription factor proteins, such as Dicer and Argonout,
for regulating non-coding (NC)RNA is still considered by
the scientific community as important.55 Comprehension
of Protein Domain annotation would eventually shed
light to the narration of the transcriptomics mechanistic
insights.56 Thus, the dynamism of nucleic acids has
already been unveiled with the DNA-biped nanoAugust 2017 | Vol. 21 | No. 2
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modeling.57 These theoretical bases are important as the
cornerstone for nanobiomedicine-based drug development.

This multidisciplinary effort could be a major trend in
the scientific community.

The application of transcriptomics-based bioinformatics
in drug design is already in sight. Pharmaceutical research
has provided the clinical application for cancer, HIV/
AIDS, hepatitis, and others.58 However, due to the
incomplete understanding of nano-based modelling of
drug-target interaction, only a handful of products are
available on the market.58 The different nature of
molecules in nano-scale size should be considered when
constructing a solid computational model. Thus, a new
field that incorporates bioinformatics and nanomedicine
has already born. Nanoinformatics is the intersection
between bioinformatics and nanobiotechnology.59 The
advancements in nanomaterials have made it possible to
scale them into the realm of nanobiomedicine.60 However,
real applications of nanoinformatics remain to be seen.
These nano-based computations need strong computational power as provided in the computer clusters and
supercomputers.61
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